Table 2.
Predictive factors for OS by univariate and multivariate analysis
| Univariate analyses | Multivariate analyses | ||
|---|---|---|---|
| HR(95%CI) P valueΦ |
HR(95%CI) P valueΦ |
||
| Gender | Male versus female |
0.79(0.43–1.45) 0.447 |
|
| Age (years) | < 59 versus ≥ 59 |
1.00(0.52–1.91) 0.991 |
|
| ECOG PS | 1–2 versus 0 |
3.72(1.91–7.26) < 0.001 |
1.19(0.43–3.26) 0.737 |
| Smoker | Yes versus no |
1.22(0.60–2.50) 0.578 |
|
| LDH | Low versus high |
0.49(0.26–0.91) 0.024 |
1.89(0.75–4.74) 0.174 |
| Treatment lines | 1st versus ≥ 2nd |
0.15(0.07–0.32) < 0.001 |
0.33(0.12–0.93) 0.037 |
| Lung metastasis | Yes versus no |
5.49(2.86–10.54) < 0.001 |
2.31(1.03–5.14) 0.041 |
| Liver metastasis | Yes versus no |
15.80(2.17–114.77) 0.006 |
6.76(0.86–52.97) 0.069 |
| ApoB baseline | Low versus high |
3.95(2.17–7.20) < 0.001 |
2.26(0.79–6.48) 0.130 |
| CHO baseline | Low versus High |
2.49(1.34–4.64) 0.004 |
1.57(0.34–7.23) 0.562 |
| HDL-C baseline | Low versus high |
3.83(1.75–8.35) < 0.001 |
6.30(1.82–21.80) 0.004 |
| LDL-C baseline | Low versus high |
2.73(1.49–4.99) 0.001 |
0.33(0.07–1.68) 0.183 |
| ApoB alteration | Reduction versus elevation |
0.41(0.22–0.78) 0.006 |
1.78(0.64–4.92) 0.268 |
| ApoA-I alteration | Reduction versus elevation |
6.36(2.68–15.12) < 0.001 |
1.22(0.26–5.67) 0.804 |
| HDL-C alteration | Reduction versus elevation |
4.26(2.19–8.13) < 0.001 |
4.59(1.20–17.63) 0.026 |
Abbreviations: OS overall survival, ECOG PS Eastern Cooperative Oncology Group performance status, LDH lactate dehydrogenase, ApoB apolipoprotein B, ApoA-I apolipoprotein A-I, CHO Cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TG Triglyceride, HR hazard ratio, CI Confidence interval
ΦValues in boldface indicate P values < 0.05